ArticleThe Journal of investigative dermatology2013
MicroRNAs as an emerging target for melanoma therapy.
Article in The Journal of investigative dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Exosomal Non-coding RNAs: A New Approach to Melanoma Diagnosis and Therapeutic Strategy.Current medicinal chemistry · 2024Review
- Upregulation of the novel lncRNA U731166 is associated with migration, invasion and vemurafenib resistance in melanoma.Journal of cellular and molecular medicine · 2022Article
- MicroRNA-27b inhibits the development of melanoma by targeting MYC.Oncology letters · 2021Article
- Review
- MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets onCell death discovery · 2017Article
- The role of microRNA-26a in human cancer progression and clinical application.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- The anti-melanoma activity and oncogenic targets of hsa-miR-15a-5p.RNA & disease (Houston, Tex.) · 2016Article
- Antiproliferative and Pro-Apoptotic Effects of MiR-4286 Inhibition in Melanoma Cells.PloS one · 2016Article
- An updated review of mechanotransduction in skin disorders: transcriptional regulators, ion channels, and microRNAs.Cellular and molecular life sciences : CMLS · 2015Review
- Could the Anti-Chaperone VER155008 Replace Temozolomide for Glioma Treatment.Journal of Cancer · 2015Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
Despite the growing focus on microRNAs (miRNAs) as novel diagnostic tools and therapeutic targets in cancer, global characterization of miRNA expression patterns and their specific targets in melanoma has lagged. In this issue, Reuland et al. (2012) identify miR-26a as being specifically downregulated in human melanoma cells. They further establish Silencer of Death Domains as a novel target for miR-26a, which functionally mediates melanoma cell death. These findings suggest that miR-26a may serve as a promising novel therapy for subsets of melanoma.
Indexed as
Identifiers
23594536What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.